Coya Therapeutics (COYA) EBITDA Margin (2023 - 2025)
Historic EBITDA Margin for Coya Therapeutics (COYA) over the last 3 years, with Q3 2025 value amounting to 68.07%.
- Coya Therapeutics' EBITDA Margin changed N/A to 68.07% in Q3 2025 from the same period last year, while for Sep 2025 it was 516.02%, marking a year-over-year decrease of 3974700.0%. This contributed to the annual value of 484.58% for FY2024, which is 3533600.0% down from last year.
- As of Q3 2025, Coya Therapeutics' EBITDA Margin stood at 68.07%.
- Coya Therapeutics' EBITDA Margin's 5-year high stood at 30.36% during Q4 2023, with a 5-year trough of 208681.1% in Q4 2024.
- In the last 3 years, Coya Therapeutics' EBITDA Margin had a median value of 2974.24% in 2025 and averaged 31431.58%.
- Its EBITDA Margin has fluctuated over the past 5 years, first crashed by 2000000000bps in 2024, then soared by 13432100bps in 2025.
- Quarter analysis of 3 years shows Coya Therapeutics' EBITDA Margin stood at 30.36% in 2023, then plummeted by -687559bps to 208681.1% in 2024, then skyrocketed by 100bps to 68.07% in 2025.
- Its EBITDA Margin was 68.07% in Q3 2025, compared to 3916.29% in Q2 2025 and 2974.24% in Q1 2025.